索拉非尼防治肝癌肝移植术后复发的研究进展

周林; 郑永根; 杜国盛

doi:10.3969/j.issn.1674-7445.2014.05.003

索拉非尼防治肝癌肝移植术后复发的研究进展

doi: 10.3969/j.issn.1674-7445.2014.05.003

周林^{1, 2},
郑永根^{2, 3},
杜国盛^1, ,

1.
100091 北京, 解放军第309医院全军器官移植研究所肝胆外科
2.
海南五指山市75559部队医院
3.
解放军总医院肝胆外科

基金项目:

首都临床特色应用研究 Z111107058811008

详细信息

通讯作者:
杜国盛,Email:duguosheng@medmail.com.cn

中图分类号: R617
计量
- 文章访问数: 78
- HTML全文浏览量: 96
- PDF下载量: 5
- 被引次数: 0
出版历程
- 收稿日期: 2014-06-01
- 刊出日期: 2014-09-15

摘要

- 索拉非尼 /
- 肝移植 /
- 肝细胞癌 /
- 肿瘤复发

HTML全文

参考文献(59)

[1]	Kew MC. Hepatocellular carcinoma in developing countries:prevention, diagnosis and treatment[J]. World J Hepatol,2012,4(3):99-104. doi: 10.4254/wjh.v4.i3.99
[2]	European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC Clinical Practice Guidelines:management of hepatocellular carcinoma[J]. J Hepatol,2012,56(4):908-943. doi: 10.1016/j.jhep.2011.12.001
[3]	Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822):1245-1255. doi: 10.1016/S0140-6736(11)61347-0
[4]	Surveillance Research Program, National Cancer Institute. Fast stats:an interactive tool for access to SEER cancer statistics[EB/OL]. (2011-08-15)[2011-11-10]. http://seer.cancer.gov/faststats.
[5]	Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma[J]. Liver Cancer,2012,1(2):71-82. doi: 10.1159/000342403
[6]	Lin S, Hoffmann K, Schemmer P. Treatment of hepatocellular carcinoma:a systematic review[J]. Liver Cancer,2012,1(3/4):144-158. http://cn.bing.com/academic/profile?id=1980682169&encoded=0&v=paper_preview&mkt=zh-cn
[7]	Pfiffer TE, Seehofer D, Nicolaou A, et al. Recurrent hepatocellular carcinoma in liver transplant recipients:parameters affecting time to recurrence, treatment options and survival in the sorafenib era[J]. Tumori,2011,97(4):436-441. http://cn.bing.com/academic/profile?id=2346524883&encoded=0&v=paper_preview&mkt=zh-cn
[8]	Silva MF, Sherman M. Criteria for liver transplantation for HCC:what should the limits be?[J]. J Hepatol,2011,55(5):1137-1147. doi: 10.1016/j.jhep.2011.05.012
[9]	Zarrinpar A, Kaldas F, Busuttil RW. Liver transplantation for hepatocellular carcinoma:an update[J]. Hepatobiliary Pancreat Dis Int,2011,10(3):234-242. doi: 10.1016/S1499-3872(11)60039-8
[10]	Fan HL, Chen TW, Hsieh CB, et al. Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria[J]. Am J Surg,2010,200(2):252-257. doi: 10.1016/j.amjsurg.2009.07.049
[11]	Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma:an update[J]. Hepatology,2011,53(3):1020-1022. doi: 10.1002/hep.24199
[12]	Welker MW, Bechstein WO, Zeuzem S, et al. Recurrent hepatocellular carcinoma after liver transplantation:an emerging clinical challenge[J]. Transpl Int,2013,26(2):109-118. doi: 10.1111/tri.2013.26.issue-2
[13]	Kornberg A, Küpper B, Tannapfel A, et al. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients:clinical patterns and outcome variables[J]. Eur J Surg Oncol,2010,36(3):275-280. doi: 10.1016/j.ejso.2009.10.001
[14]	Kim HR, Cheon SH, Rha SY, et al. Treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Asia Pac J Clin Oncol,2011,7(3):258-269. doi: 10.1111/ajco.2011.7.issue-3
[15]	Roh YN, David Kwon CH, Song S, et al. The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation[J]. Clin Transplant,2014,28(1):141-148. doi: 10.1111/ctr.12286
[16]	Davis E, Wiesner R, Valdecasas J, et al. Treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Liver Transpl,2011,17(Suppl 2):S162-S166. http://cn.bing.com/academic/profile?id=2077626674&encoded=0&v=paper_preview&mkt=zh-cn
[17]	Castroagudín JF, Molina-Pérez E, Ferreiro-Iglesias R, et al. Late recurrence of hepatocellular carcinoma after liver transplantation:is an active surveillance for recurrence needed?[J]. Transplant Proc,2012,44(6):1565-1567. doi: 10.1016/j.transproceed.2012.05.007
[18]	Park MS, Lee KW, Suh SW, et al. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation[J]. Transplantation,2014,97(1):71-77. doi: 10.1097/TP.0b013e3182a68953
[19]	Chok KS, Chan SC, Cheung TT, et al. Late recurrence of hepatocellular carcinoma after liver transplantation[J]. World J Surg,2011,35(9):2058-2062. doi: 10.1007/s00268-011-1146-z
[20]	Iacob R, Iacob S, Gheorghe L, et al. Outcome of liver transplantation for hepatocellular carcinoma:a single center experience[J]. Chirurgia,2013,108(4):446-450. http://cn.bing.com/academic/profile?id=2414624221&encoded=0&v=paper_preview&mkt=zh-cn
[21]	Sharma P, Welch K, Hussain H, et al. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD Era[J]. Dig Dis Sci,2012,57(3):806-812. doi: 10.1007/s10620-011-1910-9
[22]	Hackl C, Schlitt HJ, Kirchner GI, et al. Liver transplantation for malignancy:current treatment strategies and future perspectives[J]. World J Gastroenterol,2014,20(18):5331-5344. doi: 10.3748/wjg.v20.i18.5331
[23]	Matter MS, Decaens T, Andersen JB, et al. Targeting the mTOR pathway in hepatocellular carcinoma:current state and future trends[J]. J Hepatol,2014,60(4):855-865. doi: 10.1016/j.jhep.2013.11.031
[24]	Kawahara T, Asthana S, Kneteman NM. m-TOR inhibitors:what role in liver transplantation?[J]. J Hepatol,2011,55(6):1441-1451. doi: 10.1016/j.jhep.2011.06.015
[25]	Cholongitas E, Mamou C, Rodríguez-Castro KI, et al. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation:a systematic review[J]. Transpl Int,2014,DOI:10.1111/tri.12372[Epub ahead of print].
[26]	Vivarelli M, Dazzi A, Zanello M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma[J]. Transplantation,2010,89(2):227-231. doi: 10.1097/TP.0b013e3181c3c540
[27]	Liang W, Wang D, Ling X, et al. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma:a meta-analysis[J]. Liver Transpl,2012,18(1):62-69. doi: 10.1002/lt.v18.1
[28]	Klintmalm GB, Nashan B. The role of mTOR inhibitors in liver transplantation:reviewing the evidence[J]. J Transplant,2014:845438[Epub ahead of print]. http://cn.bing.com/academic/profile?id=2080790649&encoded=0&v=paper_preview&mkt=zh-cn
[29]	Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients:a randomized trial[J]. Am J Transplant,2012,12(3):694-705. doi: 10.1111/j.1600-6143.2011.03919.x
[30]	Menon KV, Hakeem AR, Heaton ND. Meta-analysis:recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma[J]. Aliment Pharmacol Ther,2013,37(4):411-419. doi: 10.1111/apt.12185
[31]	Wang Z, Zhou J, Fan J, et al. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma[J]. Clin Cancer Res,2008,14(16):5124-5130. doi: 10.1158/1078-0432.CCR-07-4774
[32]	Saidi RF, Shah SA, Rawson AP, et al. Treating hepatocellular carcinoma with sorafenib in liver transplant patients:an initial experience[J]. Transplant Proc,2010,42(10):4582-4584. doi: 10.1016/j.transproceed.2010.09.147
[33]	Vitale A, Volk ML, Pastorelli D, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation:a cost-benefit analysis while awaiting data on sorafenib safety[J]. Hepatology,2010,51(1):165-173. doi: 10.1002/hep.23260
[34]	Di Benedetto F, Berretta M, De Ruvo N, et al. Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?[J]. J Surg Oncol,2012,105(1):111-112. doi: 10.1002/jso.22039
[35]	Yoo EJ, Shin HS, Kim SU, et al. Orthotopic liver transplantation after the combined use of locoregional therapy and sorafenib for advanced hepatocellular carcinoma[J]. Onco Targets Ther,2013,6:755-759. http://cn.bing.com/academic/profile?id=1700204970&encoded=0&v=paper_preview&mkt=zh-cn
[36]	Frenette CT, Boktour M, Burroughs SG, et al. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation[J]. Transpl Int,2013,26(7):734-739. doi: 10.1111/tri.2013.26.issue-7
[37]	Adair A, Wigmore SJ. Sorafenib for hepatocellular carcinoma before liver transplantation[J]. Transpl Int,2013,26(11):e100-e101. doi: 10.1111/tri.2013.26.issue-11
[38]	Teng CL, Hwang WL, Chen YJ, et al. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation:a case control study[J]. World J Surg Oncol,2012,10:41. doi: 10.1186/1477-7819-10-41
[39]	Saab S, McTigue M, Finn RS, et al. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients:feasibility and efficacy[J]. Exp Clin Transplant,2010,8(4):307-313. http://cn.bing.com/academic/profile?id=2277366138&encoded=0&v=paper_preview&mkt=zh-cn
[40]	Tan WF, Qiu ZQ, Yu Y, et al. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation[J]. Acta Pharmacol Sin,2010,31(12):1643-1648. doi: 10.1038/aps.2010.124
[41]	Yoon DH, Ryoo BY, Ryu MH, et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation[J]. Jpn J Clin Oncol,2010,40(8):768-773. doi: 10.1093/jjco/hyq055
[42]	Castroagudín JF, Molina-Pérez E, Ferreiro-Iglesias R, et al. Late recurrence of hepatocellular carcinoma after liver transplantation:is an active surveillance for recurrence needed?[J]. Transplant Proc,2012,44(6):1565-1567. doi: 10.1016/j.transproceed.2012.05.007
[43]	Sposito C, Mariani L, Germini A, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation:a case-control study[J]. J Hepatol,2013,59(1):59-66. doi: 10.1016/j.jhep.2013.02.026
[44]	Waghray A, Balci B, El-Gazzaz G, et al. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Clin Transplant,2013,27(4):555-561. doi: 10.1111/ctr.12150
[45]	Pfeiffenberger J, Koschny R, Hoffmann K, et al. Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation[J]. Langenbecks Arch Surg,2013,398(8):1123-1128. doi: 10.1007/s00423-013-1114-1
[46]	Mancuso A, Airoldi A, Vigano R, et al. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinomarecurrence after liver transplantation[J]. Dig Liver Dis,2011,43(9):754. doi: 10.1016/j.dld.2011.04.022
[47]	Weinmann A, Niederle IM, Koch S, et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation[J]. Dig Liver Dis,2012,44(5):432-437. doi: 10.1016/j.dld.2011.12.009
[48]	Vitale A, Lombardi G, Ramirez Morales R, et al. Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma[J]. Dig Liver Dis,2012,44(5):361-362. doi: 10.1016/j.dld.2012.02.014
[49]	Staufer K, Fischer L, Seegers B, et al. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation[J]. Transpl Int,2012,25(11):1158-1164. doi: 10.1111/j.1432-2277.2012.01540.x
[50]	Zavaglia C, Airoldi A, Mancuso A, et al. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation:experience at a single center and review of the literature[J]. Eur J Gastroenterol Hepatol,2013,25(2):180-186. doi: 10.1097/MEG.0b013e328359e550
[51]	De Simone P, Crocetti L, Pezzati D, et al. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation[J]. Transplant Proc,2014,46(1):241-244. doi: 10.1016/j.transproceed.2013.10.035
[52]	Perricone G, Mancuso A, Belli LS, et al. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation:does mTOR inhibitors association augment toxicity?[J]. Eur J Gastroenterol Hepatol,2014,26(5):577-578. doi: 10.1097/MEG.0000000000000073
[53]	Takahara T, Nitta H, Hasegawa Y, et al. Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation:interactions between calcineurin inhibitor:two case reports[J]. Transplant Proc,2011,43(7):2800-2805. doi: 10.1016/j.transproceed.2011.06.063
[54]	Bhoori S, Toffanin S, Sposito C, et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation:a proof of principle[J]. J Hepatol,2010,52(5):771-775. doi: 10.1016/j.jhep.2010.01.025
[55]	Harper SJ, Gelson W, Harper IG, et al. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective:a single-center experience[J]. Transplantation,2011,91(1):128-132. doi: 10.1097/TP.0b013e3181fe131b
[56]	Waidmann O, Hofmann WP, Zeuzem S, et al. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation[J]. J Hepatol,2011,54(2):396-398. http://cn.bing.com/academic/profile?id=2019493792&encoded=0&v=paper_preview&mkt=zh-cn
[57]	Sotiropoulos GC, Nowak KW, Fouzas I, et al. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation[J]. Transplant Proc,2012,44(9):2754-2756. doi: 10.1016/j.transproceed.2012.09.022
[58]	Vitale A, Boccagni P, Kertusha X, et al. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?[J]. Transplant Proc,2012,44(7):1989-1991. doi: 10.1016/j.transproceed.2012.06.046
[59]	Gomez-Martin C, Bustamante J, Castroagudin JF, et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation[J]. Liver Transpl,2012,18(1):45-52. doi: 10.1002/lt.v18.1